Latest news with #Wegovy®
Malaysian Reserve
15-07-2025
- Business
- Malaysian Reserve
Faruqi & Faruqi Reminds Hims & Hers Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 25, 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Hims To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Hims between April 29, 2025 and June 22, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, July 15, 2025 /PRNewswire/ — Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Hims & Hers Health, Inc. ('Hims' or the 'Company') (NYSE: HIMS) and reminds investors of the August 25, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) that Hims was engaged in the 'deceptive promotion and selling of illegitimate, knockoff versions of Wegovy® that put patient safety at risk;' (2) that, as a result, there was a substantial risk that the Company's collaboration with Novo Nordisk would be terminated; and (3) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. On June 23, 2025, Novo Nordisk announced that it was ending its partnership with Hims, stating that Hims 'has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of 'personalization' and are disseminating deceptive marketing that put patient safety at risk.' Novo Nordisk further stated 'the 'semaglutide' active pharmaceutical ingredients that are in the knock-off drugs sold by telehealth entities and compounding pharmacies' may contain 'unsafe and illicit foreign ingredients.' On this news, Hims' stock price fell $22.24, or 34.6%, to close at $41.98 per share on June 23, 2025, thereby injuring investors. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding Hims' conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the Hims & Hers Health class action, go to or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
Malaysian Reserve
12-07-2025
- Business
- Malaysian Reserve
June in Review: 14 Top Health Press Releases
A roundup of the most newsworthy healthcare press releases from PR Newswire, including a nasal spray for sleep apnea, a landmark study in clinical cancer research and a new approach to increasing longevity. NEW YORK, July 11, 2025 /PRNewswire/ — With thousands of press releases published each month, it can be difficult to keep up with everything on PR Newswire. To help healthcare journalists and consumers stay on top of the month's most popular releases and newsworthy trends, here's a recap of some of the past month's most read- and engaged-with stories. The list below includes the headline (with a link to the full text) and an excerpt from each story. Click on the press release headlines to access accompanying multimedia assets that are available for download. Novo Nordisk terminates collaboration with Hims & Hers Health, Inc. due to concerns about their illegal mass compounding and deceptive marketingIn support of transitioning patients from knock-off versions to authentic versions of Wegovy®, Novo Nordisk began collaborating with telehealth companies. Over one month into the collaboration, Hims & Hers Health, Inc. has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of 'personalization' and are disseminating deceptive marketing that put patient safety at risk. Big4Bio and BYTE51 Announce Partnership at 2025 BIO International Convention to Make Life Sciences Intelligence Accessible to All BYTE51 provides powerful tools for exploring privately held biotech companies, allowing users to filter by scientific indications, mechanisms of action, funding stages, location, capital raised, clinical progress, investors, and partners. This empowers VCs, business developers, and startup executives alike to make faster, smarter, and more strategic decisions, all of which can benefit the diverse Big4Bio audience. Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk'VERVE-102 has the potential to be the first in vivo gene editing therapy for broad patient populations and could shift the treatment paradigm for cardiovascular disease from chronic care to one-and-done treatment,' said Ruth Gimeno, Lilly group vice president, Diabetes and Metabolic Research and Development. Mark Cuban Cost Plus Drug Company, PBC and 9amHealth Join Forces to Expand Access to Affordable Obesity Care Employees will now have access to low-cost, high-quality medications through Cost Plus Drugs, alongside 9amHealth's expert Care Team of Obesity Medicine physicians, endocrinologists, and cardiometabolic specialists—all available without long waits or costly appointments. Klotho Neuroscience, Inc. Announces an Approach To Increase Longevity and Healthy Life Span – Replace a Silenced Gene Called Alpha-Klotho ('α- KLOTHO') Recent clinical and pre-clinical studies and analysis indicates the potential to increase lifespan and reduce age-associated degeneration in multiple organ systems has be realized with a focus on the human gene called Klotho. AbbVie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient Care in Immunology 'By advancing CPTX2309 and utilizing Capstan's novel platform technology, AbbVie and Capstan aim to transform the care of those living with autoimmune diseases by developing treatments that have the potential to reset the immune system,' said Roopal Thakkar, M.D., executive vice president, research and development and chief scientific officer, AbbVie. Neuspera Medical Receives FDA Approval for First Integrated Sacral Neuromodulation (iSNM) System for Urinary Urge Incontinence 'For too long, patients have had to weigh the benefits of SNM therapy against real concerns about complications related to implanted batteries and the need for surgeries to replace it. Neuspera's integrated system provides symptom relief without these additional burdens,' said Dr. Howard Goldman, vice-chairman of Urology at the Cleveland Clinic. Shasqi Publishes Landmark Study in Clinical Cancer Research: First-in-Human Use of Click Chemistry Unlocks New Opportunities for Targeted Cancer Therapies Shasqi's Click Activated Protodrugs Against Cancer (CAPAC®) platform is a pre-targeting technology composed of a tumor binding agent and a protodrug. Administered sequentially, these components are designed to only click with each other via a click chemistry reaction occurring directly at the tumor site. This releases high concentrations of cancer drugs at the tumor while sparing healthy tissues. Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy This transaction builds on a co-development agreement Illumina established with SomaLogic in December 2021 to bring the SomaScan® Proteomics Assay onto Illumina's high-throughput next-generation-sequencing (NGS) platforms. Cochlear introduces the Baha® 7 Sound Processor and Baha SoundBand™ The Processor is the first in bone conduction to enable Bluetooth® LE Audio* and Auracast™ broadcast audio streaming capabilities. As more venues adopt Auracast technology, Baha 7 Sound Processor recipients can access audio streams in places like theaters, concert halls, lecture halls and airports, through an LE Audio-enabled smartphone. Novogene Certified for Olink® Services Across Multiple Labs; Expands Proteomics Portfolio with Olink® Reveal 'With Olink® Reveal offering deep insights into inflammatory biology, we empower researchers to accelerate biomarker discovery, translational research, and precision medicine. This recognition further enhances Novogene's leadership in comprehensive multi-omics solutions,' said Justin Lee, Novogene VP of Global Marketing. Mosanna Therapeutics Launches with $80 Million to Advance Novel Nighttime Nasal Spray for Obstructive Sleep Apnea Mosanna is pioneering a pharmaceutical solution for sleep apnea patients with MOS118, a nasal spray administered at bedtime that helps restore the body's natural airway reflex. Research has shown that, for reasons yet unknown, the natural airway reflex in OSA patients exhibits decreased activity during sleep resulting in loss of airway patency and apnea. Grady Launches Emergency Medical Helicopter in Partnership with Air Methods This cutting-edge air ambulance will be staffed entirely by Grady medical personnel – highly trained nurses, paramedics, and critical care specialists – while experienced pilots from Air Methods will operate the aircraft. The partnership brings together top-tier medical care and aviation expertise to deliver life-saving interventions to patients faster than ever before. Visby Medical™ Raises up to $65 Million in New Financing Round to Accelerate Launch of Groundbreaking At-Home Sexually Transmitted Infections (STI) Test 'Visby Medical has delivered the first and only laboratory-grade STI testing solution that can be made directly accessible to individuals. We were eager to invest in Visby ahead of their FDA clearance, knowing this would represent a breakthrough moment for the diagnostics industry,' said Isaac Ro, Catalio Capital Management Partner. For more news like this, check out all of the latest health-related releases from PR Newswire. Trending Topics Among the health news that was distributed in June, the PR Newswire team was able spot several larger stories that highlight the trends shaping the industry. Men's Mental Health: Men's Mental Health Month aims to break the stigma and explore the factors that play into to the often less talked about issue. Studies released in June point looked into several contributing factors. According to Postpartum Support International, at least one in ten fathers experience postpartum depression during the perinatal period with as many as 50% of fathers suffering at the same time as their partners. On the financial side of things, Beyond Finance revealed financial distress is fueling a silent mental health crisis among men, driven by secrecy, shame and isolation. Men have reported feeling frustrated, anxious, overwhelmed and embarrassed because of their financial situation — yet nearly a quarter (22%) don't feel comfortable seeking out financial advice from anyone. Sleep Health: The Associated Professional Sleep Societies (APSS) hosted its annual meeting, SLEEP 2025, in Seattle from June 8-11. The event showcased several advances shaping the future of sleep medicine. Researchers from Huxley Medical shared data highlighting the capabilities of the SANSA home sleep apnea test. Another study, this one from Rest and SleepScore Labs, showed significant perceived improvements in sleep comfort, temperature regulation and overall sleep quality when using Rest's Evercool® products like pillowcases and sheets. Do you have a health press release to distribute? Sign up with PR Newswire to share your story with the audiences who matter most. Helping Journalists Stay Up to Date on Industry News These are just a few of the recent press releases that consumers and the media should know about. To be notified of releases relevant to their coverage area, journalists can set up a custom newsfeed with PR Newswire for Journalists. Once they're signed up, reporters, bloggers, and freelancers have access to the following free features: Customization: Users can create customized newsfeeds that will deliver relevant news right to their inbox. Newsfeed results can be targeted by keywords, industry, subject, geography, and more. Photos and Videos: Thousands of multimedia assets are available to download and include in a journalist or blogger's next story. Subject Matter Experts: Journalists will have access to ProfNet, a database of industry experts to connect with as sources or for quotes in their articles. Related Resources: Our journalist- and blogger-focused blog, Beyond Bylines, features regular media news roundups, writing tips, upcoming events, and more. About PR Newswire PR Newswire is the industry's leading press release distribution partner with an unparalleled global reach of more than 440,000 newsrooms, websites, direct feeds, journalists and influencers and is available in more than 170 countries and 40 languages. From our award-winning Content Services offerings, integrated media newsroom and microsite products, Investor Relations suite of services, paid placement and social sharing tools, PR Newswire has a comprehensive catalog of solutions to solve the modern-day challenges PR and communications teams face. For 70 years, PR Newswire has been the preferred destination for brands to share their most important news stories across the world. For questions, contact the team at
Arabian Post
12-07-2025
- Health
- Arabian Post
Singapore Welcomes Wegovy® as a New Prescription Weight‑Loss Option
A once-weekly injection of Wegovy® has become available in Singapore, marking the latest step in managing obesity as a chronic disease. The product, from Novo Nordisk, is licensed for adults and those aged 12 and above who are obese or overweight with at least one weight‑related condition such as hypertension, type 2 diabetes or dyslipidemia. The drug works by mimicking the gut hormone GLP‑1, promoting a sense of fullness and reducing food intake when combined with healthier diet and exercise regimes. Its introduction follows approval by the Health Sciences Authority on 28 February 2025 for use among adolescents with obesity—a first in the region. Over 600,000 adult Singaporeans are classified as obese, a figure that underlines the public health urgency given the hundreds of comorbidities associated with obesity. The rollout of Wegovy® offers a medically guided therapy for a condition too often dismissed as a lifestyle issue. ADVERTISEMENT Clinical experts argue obesity stems from complex biological factors, ranging from genetics to hormonal imbalances. Dr Abel Soh, chair of the Endocrine and Metabolic Society of Singapore, says, 'Obesity is not simply the result of lifestyle choices—it is a medically recognised chronic disease influenced by a complex interplay of genetics, hormones and environment'. Approval comes amid global strain on semaglutide supplies. Local clinics previously stocked Ozempic and Rybelsus and faced intermittent shortages, with expectant Wegovy® shipments deferred until 2026 according to some medical guides. Private clinics were unable to reference branded drugs until local stock arrived, due to regulatory restrictions. Available through prescription in private settings, Wegovy® will be offered alongside diet and exercise interventions. The injectable is indicated for chronic use; ongoing physician oversight is advised. Regulatory approval includes a requirement to review treatment after 12 weeks in adolescents if BMI reduction falls below 5% on the full 2.4 mg dose. Globally, Wegovy® was first authorised in the US in June 2021, followed by EU approval in early 2022. Earlier, in Singapore, semaglutide received approval under Ozempic's label starting March 2023 for diabetic therapy. The drug's effectiveness has been supported by the STEP clinical programmes, showing average weight reductions of between 10–15% over periods of 68 to 104 weeks. Benefits extend beyond weight loss to metabolic health improvements, including lower blood pressure and decreased cholesterol. Local uptake may mirror global patterns, where appetite suppression and metabolic regulation paired with lifestyle changes have delivered sustainable weight loss without surgery. However, supply challenges persist: healthcare providers warn that stocks may remain tight, with some expect delays or patient referrals under the Ozempic brand. Novo Nordisk has also updated its savings programme for Wegovy®, making it more accessible to cash‑paying patients. The initiative aims to reduce financial barriers, although uptake and cost‑effectiveness will depend on real‑world pricing and insurance coverage.
Arabian Post
12-07-2025
- Health
- Arabian Post
Wegovy® (semaglutide 2.4mg) by Novo Nordisk is now Available in Singapore for Weight Management
Wegovy® is indicated for chronic weight management in adults and adolescents (12+) with obesity or overweight and at least one related health condition. The once-weekly injectable supports weight loss when used alongside a reduced-calorie diet and increased physical activity. The launch marks a step toward evidence-based, compassionate treatment of obesity as a chronic disease—not a personal failing. SINGAPORE – Media OutReach Newswire – 12 July 2025 – A significant advancement in weight management has arrived for Singaporeans. Novo Nordisk, a global healthcare company focused on defeating serious chronic diseases, has announced the availability of Wegovy® (semaglutide 2.4mg) in Singapore. Wegovy® (semaglutide 2.4mg) is a once-weekly injectable treatment indicated for chronic weight management in adults and adolescents (aged 12 and above) living with obesity (BMI ≥30 kg/m²), or who are overweight (BMI ≥27 kg/m² to <30 kg/m²) with at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia1. It is used alongside a reduced-calorie diet and increased physical activity, supporting Singapore's efforts to improve population health. The treatment works by addressing one of the underlying biological drivers of obesity. Wegovy® (semaglutide 2.4mg) is a GLP-1 receptor agonist with 94% similarity to the body's natural GLP-1 hormone. It activates receptors involved in appetite regulation, helping individuals feel full sooner and reduce food intake1. This mechanism supports weight loss when combined with sustainable lifestyle changes. ADVERTISEMENT The availability of Wegovy® (semaglutide 2.4mg) comes as obesity continues to pose a significant health burden in Singapore. An estimated 600,000 adults are currently living with obesity2–4, a condition associated with more than 200 health complications5. Despite its prevalence and medical complexity, obesity remains heavily stigmatised—often misunderstood as merely the result of poor personal choices. Individuals living with obesity frequently face discrimination and mental health challenges which further isolate them. This misplaced blame, rather than targeting the disease itself, creates barriers to and slows the advancement of effective obesity treatment. Recognised by World Health Organization as a chronic disease6, obesity requires compassionate evidence-based care. The launch of Wegovy® (semaglutide 2.4mg) in Singapore provides a new treatment option for weight management available through private prescription. Dr Abel Soh, Abel Soh Diabetes, Thyroid and Endocrine Clinic and Chairperson for Endocrine and Metabolic Society of Singapore (EMSS) stated, 'Obesity is not simply the result of lifestyle choices — it is a medically recognised chronic disease influenced by a complex interplay of genetics, hormones, and environment. In my clinical practice, I see firsthand how many individuals blame themselves when in fact, their biology is often working against them. It's time we shift the conversation from blame to support in the management of individuals with obesity' Lifestyle factors in Singapore further contribute to the challenge. In Singapore's demanding work culture—where full-time employees work an average of 44.6 hours per week7, with time constraints and fatigue frequently cited as barriers to maintaining regular physical activity. These circumstances underscore the importance of comprehensive treatment strategies that facilitate the adoption of healthier lifestyles, including increased physical activity and a reduced-calorie diet, as integral components of long-term weight management. Mr Vincent Siow, General Manager, Novo Nordisk Singapore, said 'With treatments like Wegovy® (semaglutide 2.4mg) now available in Singapore, we have an opportunity to provide healthcare professionals with more evidence-based options to support their patients in regaining control of their health and improving long-term outcomes.' References: Wegovy Singapore Prescribing Information, February 2025 Cuciureanu M, Caratașu CC, Gabrielian L, Frăsinariu OE, Checheriță LE, Trandafir LM, Stanciu GD, Szilagyi A, Pogonea I, Bordeianu G, Soroceanu RP, Andrițoiu CV, Anghel MM, Munteanu D, Cernescu IT, Tamba BI. 360-Degree Perspectives on Obesity. Medicina (Kaunas). 2023 Jun 9;59(6):1119. doi: 10.3390/medicina59061119. PMID: 37374323; PMCID: PMC10304508. World Obesity. Retrieved from World Obesity. Retrieved from Scott I. Kahan, MD, MPH. Practical Strategies for Engaging Individuals With Obesity in Primary Care. Mayo Clin Proc. 2018;93(3):351-359 2. CDC, Cancers Associated with Overweight and Obesity Makeup 40 percent of Cancers Diagnosed in the United States. Available at World Health Organization. (2024). Obesity and As accessed on 22nd May 2025. Leu J, Rebello SA, Sargent GM, Kelly M, Banwell C. Hard work, long hours, and Singaporean young adults' health. A qualitative study. Frontiers in Public Health. 2023; 11. Hashtag: #NovoNordisk #Wegovy The issuer is solely responsible for the content of this announcement. About Novo Nordisk Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs around 77,400 people in 80 countries and markets its products in around 170 countries. In Singapore, Novo Nordisk has been present since 1997 and has approximately 100 employees. For more information, visit
The Sun
12-07-2025
- Health
- The Sun
Wegovy® (semaglutide 2.4mg) by Novo Nordisk is now Available in Singapore for Weight Management
SINGAPORE - Media OutReach Newswire - 12 July 2025 - A significant advancement in weight management has arrived for Singaporeans. Novo Nordisk, a global healthcare company focused on defeating serious chronic diseases, has announced the availability of Wegovy® (semaglutide 2.4mg) in Singapore. Wegovy® (semaglutide 2.4mg) is a once-weekly injectable treatment indicated for chronic weight management in adults and adolescents (aged 12 and above) living with obesity (BMI ≥30 kg/m²), or who are overweight (BMI ≥27 kg/m² to <30 kg/m²) with at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia1. It is used alongside a reduced-calorie diet and increased physical activity, supporting Singapore's efforts to improve population health. The treatment works by addressing one of the underlying biological drivers of obesity. Wegovy® (semaglutide 2.4mg) is a GLP-1 receptor agonist with 94% similarity to the body's natural GLP-1 hormone. It activates receptors involved in appetite regulation, helping individuals feel full sooner and reduce food intake1. This mechanism supports weight loss when combined with sustainable lifestyle changes. The availability of Wegovy® (semaglutide 2.4mg) comes as obesity continues to pose a significant health burden in Singapore. An estimated 600,000 adults are currently living with obesity2-4, a condition associated with more than 200 health complications5. Despite its prevalence and medical complexity, obesity remains heavily stigmatised—often misunderstood as merely the result of poor personal choices. Individuals living with obesity frequently face discrimination and mental health challenges which further isolate them. This misplaced blame, rather than targeting the disease itself, creates barriers to and slows the advancement of effective obesity treatment. Recognised by World Health Organization as a chronic disease6, obesity requires compassionate evidence-based care. The launch of Wegovy® (semaglutide 2.4mg) in Singapore provides a new treatment option for weight management available through private prescription. Dr Abel Soh, Abel Soh Diabetes, Thyroid and Endocrine Clinic and Chairperson for Endocrine and Metabolic Society of Singapore (EMSS) stated, 'Obesity is not simply the result of lifestyle choices — it is a medically recognised chronic disease influenced by a complex interplay of genetics, hormones, and environment. In my clinical practice, I see firsthand how many individuals blame themselves when in fact, their biology is often working against them. It's time we shift the conversation from blame to support in the management of individuals with obesity' Lifestyle factors in Singapore further contribute to the challenge. In Singapore's demanding work culture—where full-time employees work an average of 44.6 hours per week7, with time constraints and fatigue frequently cited as barriers to maintaining regular physical activity. These circumstances underscore the importance of comprehensive treatment strategies that facilitate the adoption of healthier lifestyles, including increased physical activity and a reduced-calorie diet, as integral components of long-term weight management. Mr Vincent Siow, General Manager, Novo Nordisk Singapore, said 'With treatments like Wegovy® (semaglutide 2.4mg) now available in Singapore, we have an opportunity to provide healthcare professionals with more evidence-based options to support their patients in regaining control of their health and improving long-term outcomes.' References: 1. Wegovy Singapore Prescribing Information, February 2025 2. Cuciureanu M, Caratașu CC, Gabrielian L, Frăsinariu OE, Checheriță LE, Trandafir LM, Stanciu GD, Szilagyi A, Pogonea I, Bordeianu G, Soroceanu RP, Andrițoiu CV, Anghel MM, Munteanu D, Cernescu IT, Tamba BI. 360-Degree Perspectives on Obesity. Medicina (Kaunas). 2023 Jun 9;59(6):1119. doi: 10.3390/medicina59061119. PMID: 37374323; PMCID: PMC10304508. 3. World Obesity. Retrieved from 4. World Obesity. Retrieved from 5. Scott I. Kahan, MD, MPH. Practical Strategies for Engaging Individuals With Obesity in Primary Care. Mayo Clin Proc. 2018;93(3):351-359 2. CDC, Cancers Associated with Overweight and Obesity Makeup 40 percent of Cancers Diagnosed in the United States. Available at 6. World Health Organization. (2024). Obesity and As accessed on 22nd May 2025. 7. Leu J, Rebello SA, Sargent GM, Kelly M, Banwell C. Hard work, long hours, and Singaporean young adults' health. A qualitative study. Frontiers in Public Health. 2023; 11. Hashtag: #NovoNordisk #Wegovy The issuer is solely responsible for the content of this announcement.
